Baltimore, D., M.F. Jacobson, J. Asso, and A.S. Huang. 1969. The formation of poliovirus proteins. Cold Spring Harbor Symposium in Quantitative Biology 34:741-746.

Binford, S.L., F. Maldonado, M.A. Brothers, P.T. Weady, L.S. Zalman, J.W. Meador, 3rd, D.A. Matthews, and A.K. Patick. 2005. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrobial Agents and Chemotherapy 49(2):619-626.

Bodian, D. 1952. Experimental studies on passive immunization against poliomyelitis. II. The prophylactic effect of human gamma globulin on paralytic poliomyelitis in cynomolgus monkeys after virus feeding. American Journal of Hygiene 56:78-89.

Bodian, D. 1955. Emerging concept of poliomyelitis infection. Science 122:105.

Bodian, D., and D.M. Horstmann. 1965. Polioviruses. In Viral and Rickettsial Infections of Man, fourth ed. F.L. Horsfall, Jr. and I. Tamm, Eds. J.B. Lippincott, Philadelphia.

Carr, J., J. Ives, L. Kelly, R. Lambkin, J. Oxford, D. Mendel, L. Tai, and N. Roberts. 2002. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Research 54(2):79-88.

CDC (Centers for Disease Control and Prevention). 2005a. Conclusions and recommendations of the advisory committee on poliomyelitis eradication—Geneva, Switzerland, October 2005. Morbidity and Mortality Weekly Report 54(46):1186-1188.

CDC. 2005b. Poliovirus infections in four unvaccinated children—Minnesota, August-October 2005. Morbidity and Mortality Weekly Report 54(41):1053-1055.

Census Bureau, Population Division, International Programs Center. 2005. IDB Summary Demographic Data. Accessed online 12/16/05 at

Coffin, J.M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267(5197):483-489.

Collett, M.S. 2005. Capsid inhibitors: a path to polio antiviral drugs. Presented at the Workshop on Development of a Polio Antiviral, National Research Council, November 1, 2005, Washington, DC.

Crotty, S., D. Maag, J.J. Arnold, W. Zhong, J.Y. Lau, Z. Hong, R. Andino, and C.E. Cameron. 2000. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nature Medicine 6(12):1375-1379. Erratum in: Nature Medicine 7(2):255.

Crowder, S., and K. Kirkegaard. 2005. Trans-dominant inhibition of RNA viral replication can slow growth of drug-resistant viruses. Nature Genetics 37(7):665-666.

de la Torre, J.C., E. Wimmer, and J.J. Holland. 1990. Very high frequency of reversion to guanidine resistance in clonal pools of guanidine-dependent type 1 poliovirus. Journal of Virology 64(2):664-667.

DiMasi, J.A., R.W. Hansen, and H.G. Grabowski. 2003. The price of innovation: new estimates of drug development costs. Journal of Health Economics 22:151-185.

Domingo, E., J. Holland, and P. Ahlquist. 1988. RNA Genetics. CRC Press, Boca Raton.

Duintjer Tebbens, R.J., M.A. Pallansch, O.M. Kew, V.M. Caceres, R.W. Sutter, and K.M. Thompson. 2005. A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. American Journal of Epidemiology 162(4):358-372.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement